FDA Approves Vertex’s Non-Opioid Painkiller Journavx, Offering New Alternative for Acute Pain

The U.S. Food and Drug Administration (FDA) has approved Vertex Pharmaceuticals’ (NASDAQ:VRTX) non-opioid drug Journavx for acute pain, marking a breakthrough in pain management. Unlike traditional opioids, which activate the brain’s reward system and risk addiction, Journavx works by blocking pain signals at their source.

Vertex has priced Journavx at $15.50 per 50 mg pill in the U.S. Shares of the company jumped nearly 4% in extended trading following the announcement.

Richard Rosenquist, chairman of the Pain Management Department at Cleveland Clinic, highlighted the significance of this approval, stating that new pain management options have been lacking. However, challenges remain as insurers and hospitals may still favor opioids. Vertex’s COO Stuart Arbuckle emphasized the company’s focus on ensuring insurance coverage and accessibility.

The Institute for Clinical and Economic Review (ICER) raised concerns about cost-effectiveness, noting that the drug is viable at lower prices, particularly if it reduces opioid dependency.

FDA approval was based on two late-stage trials, demonstrating that Journavx significantly reduced surgical pain compared to placebo. Acute pain, defined as lasting less than three months, affects millions annually. Vertex estimates that over 80 million U.S. patients receive prescriptions for acute pain each year.

Analyst Myles Minter from William Blair projects Journavx sales to reach $3.7 billion by 2030. While the drug presents a promising alternative to opioids, its commercial success hinges on adoption by healthcare providers and insurers.

This FDA approval marks a pivotal moment in addressing the opioid crisis, offering a safer alternative for pain relief.